Workflow
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use
BDRXBiodexa Pharmaceuticals PLC(BDRX) Newsfilter·2025-02-24 13:30

Core Insights - Biodexa Pharmaceuticals has received allowance for a U.S. patent covering its oral rapamycin nanoparticle preparations, known as eRapa, which is set to issue on March 4, 2025, and is expected to expire in March 2034 [1][2] - The company plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) in the next quarter, with substantial funding from a 17milliongrantfromtheCancerPreventionResearchInstituteofTexas(CPRIT)[1][2]−eRapaisdesignedtoimprovethebioavailabilityandreducetoxicityassociatedwithexistingformsofrapamycin,leveragingnanotechnologyandpH−sensitivepolymers[2][5]CompanyOverview−BiodexaPharmaceuticalsisaclinical−stagebiopharmaceuticalcompanyfocusedondevelopinginnovativetreatmentsfordiseaseswithunmetmedicalneeds,includingeRapaforFAPandotherprogramstargetingtype1diabetesandaggressiverarebraincancers[4][8]−Thecompanyhasaproprietaryoraltabletformulationofrapamycin,whichactsasanmTORinhibitor,targetingpathwaysinvolvedincellularmetabolismandtumorigenesis[2][5]FundingandSupport−CPRIThasawardedatotalof17 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) [1][2] - eRapa is designed to improve the bioavailability and reduce toxicity associated with existing forms of rapamycin, leveraging nanotechnology and pH-sensitive polymers [2][5] Company Overview - Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including eRapa for FAP and other programs targeting type 1 diabetes and aggressive rare brain cancers [4][8] - The company has a proprietary oral tablet formulation of rapamycin, which acts as an mTOR inhibitor, targeting pathways involved in cellular metabolism and tumorigenesis [2][5] Funding and Support - CPRIT has awarded a total of 2.9 billion in grants to Texas research institutions, supporting cancer research and prevention initiatives, which includes funding for Biodexa's Phase 3 study [3] - The funding from CPRIT is matched by Biodexa's contributions of $8.5 million, demonstrating a strong commitment to advancing cancer treatment research [2]